Ernexa Therapeutics (NASDAQ: ERNA) furnishes new February 2026 investor presentation

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Ernexa Therapeutics Inc. furnished an updated investor presentation on February 26, 2026, as Exhibit 99.1 to a Form 8-K. The deck refreshes a prior presentation from December 11, 2025 and is also available through the Investor Relations section of the company’s website.

The company explains that it routinely uses its website to share press releases, investor presentations and financial information, and encourages investors to monitor the News and Investor Relations pages. The material in Item 7.01 and Exhibit 99.1 is furnished, not filed, and is not subject to Exchange Act Section 18 liabilities or automatically incorporated into other SEC filings.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

02/26/2026 - 04:31 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 26, 2026

Ernexa Therapeutics Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware

001-11460

31-1103425

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

1035 Cambridge Street, Suite 18A
Cambridge, MA		02141
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 798-6700

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol		Name of each exchange on which registered
Common Stock, par value $0.005 per share		ERNA		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934:

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01

Regulation FD Disclosure.

On February 26, 2026, Ernexa Therapeutics Inc., a Delaware corporation (the “Company”, “we”, “us”, or “our”), made available an updated presentation for investors. This presentation updates the presentation posted on December 11, 2025. A copy of this updated presentation is attached hereto as Exhibit 99.1 and incorporated by reference in this Item 7.01. A copy of the presentation is also available on our website at https://investor.ernexatx.com.

Without limiting the generality of the foregoing, the “Forward-Looking Statements” disclosure contained in the Investor Presentation is incorporated by reference into this Item 7.01.

Use of our Website to Distribute Material Company Information

We use our website as a channel of distribution for important Company information. We routinely post on our website important information, including press releases, investor presentations and financial information, which may be accessed by clicking on either the “News” or “Investor Relations” sections of www.ernexatx.com. We may also use our website to expedite public access to time-critical information regarding our Company in advance of or in lieu of distributing a press release or a filing with the Securities and Exchange Commission (the “SEC”) disclosing the same information. Therefore, investors should look to the “News” or “Investor Relations” sections of our website for important and time-critical information. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when certain new information is made available on our website. Information contained on, or accessible through, our website is not a part of and is not incorporated by reference in this Current Report on Form 8-K or in any of our other filings with the SEC.

The information contained in this Item 7.01, including in Exhibit 99.1 attached hereto, is “furnished” and not “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. Such information shall not be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, except to the extent such other filing specifically incorporates such information by reference.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Ernexa Therapeutics Investor Presentation – February 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

-2-

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	Ernexa Therapeutics Inc.

Dated: February 26, 2026	By:	/s/ Sanjeev Luther
		Sanjeev Luther President and Chief Executive Officer

-3-

Exhibit 99.1

Source: View Original Filing on SEC EDGAR

FAQ

What did Ernexa Therapeutics (ERNA) disclose in its latest Form 8-K?

Ernexa Therapeutics furnished an updated investor presentation dated February 2026 as Exhibit 99.1 to a Form 8-K. The presentation replaces a prior version from December 11, 2025 and is intended to provide refreshed information for current and prospective investors.

Where can investors access Ernexa Therapeutics’ February 2026 investor presentation?

Investors can access Ernexa Therapeutics’ February 2026 investor presentation as Exhibit 99.1 to the Form 8-K and on the company’s website at https://investor.ernexatx.com. It is typically available in the News or Investor Relations sections alongside other company disclosures and materials.

How does Ernexa Therapeutics (ERNA) use its website for investor information?

Ernexa Therapeutics uses its website as a distribution channel for important information, including press releases, investor presentations and financial data. The company notes it may post time-critical updates in the News or Investor Relations sections in advance of, or instead of, issuing press releases or additional SEC filings.

Is the Ernexa Therapeutics investor presentation considered filed or furnished with the SEC?

The investor presentation attached as Exhibit 99.1 is expressly described as “furnished” rather than “filed” for Exchange Act purposes. As furnished material under Item 7.01, it is not subject to Section 18 liability and is not incorporated into other SEC filings unless specifically referenced.

Can information on Ernexa Therapeutics’ website be treated as part of its SEC filings?

The company states that information contained on or accessible through its website is not part of, and is not incorporated by reference in, its SEC reports. Only materials explicitly incorporated by reference in specific filings become part of those regulatory documents for legal and disclosure purposes.

Filing Exhibits & Attachments

37 documents

Ernexa Therapeutics (NASDAQ: ERNA) furnishes new February 2026 investor presentation

Rhea-AI Filing Summary

Positive

Negative